A5089083661- Advanced Radiotherapy Techniques
- Lung Cancer Diagnosis and Treatment
- Lung Cancer Treatments and Mutations
- Prostate Cancer Diagnosis and Treatment
- Cancer Immunotherapy and Biomarkers
- Radiomics and Machine Learning in Medical Imaging
- Radiation Dose and Imaging
- Prostate Cancer Treatment and Research
- Economic and Financial Impacts of Cancer
- Cancer survivorship and care
- Head and Neck Cancer Studies
- Medical Imaging Techniques and Applications
- Endometrial and Cervical Cancer Treatments
- Health Systems, Economic Evaluations, Quality of Life
- Hepatocellular Carcinoma Treatment and Prognosis
- Management of metastatic bone disease
- Inflammatory Biomarkers in Disease Prognosis
- Lung Cancer Research Studies
- Nonmelanoma Skin Cancer Studies
- Effects of Radiation Exposure
- Pancreatic and Hepatic Oncology Research
- Radiation Therapy and Dosimetry
- Immune cells in cancer
- Vascular Tumors and Angiosarcomas
- Dermatologic Treatments and Research
Albert Einstein College of Medicine
2016-2025
Montefiore Medical Center
2016-2025
Montefiore Einstein Comprehensive Cancer Center
2023-2025
Jacobi Medical Center
2013
New York Medical College
1997-2003
Lady of Mercy Medical Center
1997-2003
Yeshiva University
1997
PURPOSE Standard therapy for locally advanced non–small-cell lung cancer (LA-NSCLC) is concurrent chemoradiotherapy followed by adjuvant durvalumab. For biomarker-selected patients with LA-NSCLC, we hypothesized that sequential pembrolizumab and risk-adapted radiotherapy, without chemotherapy, would be well-tolerated effective. METHODS Patients stage III NSCLC or unresectable II an Eastern Cooperative Oncology Group performance status of 0-1 were eligible this trial. a PD-L1 tumor proportion...
Abstract Non-small cell lung cancer (NSCLC) is the leading cause of mortality worldwide. For patients who develop progressive disease after treatment with chemotherapy and immunotherapy, options are limited. Here, we report results a Phase II clinical trial where twenty-nine advanced, previously treated NSCLC were stereotactic body radiotherapy (SBRT) targeting single site along CDX-301, recombinant human Fms-like tyrosine kinase 3 ligand (FLT3L). The primary study endpoint was...
Objective: Several dose metrics in the categories—homogeneity, coverage, conformity and gradient have been proposed literature for evaluating treatment plan quality. In this study, we applied these to characterize identify quality that would merit assessment lung stereotactic body radiation therapy (SBRT) distributions. Methods: Treatment plans of 90 SBRT patients, comprising 91 targets, treated our institution were retrospectively reviewed. Dose calculations performed using anisotropic...
To investigate whether photon or proton-based stereotactic body radiation therapy (SBRT is the preferred modality for high dose hypofractionation prostate cancer treatment. Achievable distributions were compared when uncertainties in target positioning and range appropriately accounted for.10 patients with previously treated at our institution (Montefiore Medical Center) SBRT using volumetric modulated arc (VMAT) identified. MRI images fused to treatment planning CT allowed accurate organ...
Aim: Financial toxicity (FT) describes patients' burden from out-of-pocket medical treatment costs. We studied associations between patient-reported pretreatment FT, socioeconomic status and clinical outcomes for locally advanced non-small-cell lung cancer (LA-NSCLC) patients. Methods: Patients received chemoradiotherapy completed the European Organization Research Treatment of Cancer Core Quality Life Questionnaire (EORTC QLQ-C30) quality life assessment before treatment. One question asks...
Financial toxicity (FT) is a significant concern for patients with cancer. We reviewed prospectively collected data to explore associations FT among undergoing concurrent, definitive chemoradiation therapy (CRT) within diverse, urban, academic radiation oncology department.Patients received CRT in 1 of 3 prospective trials. was evaluated before (baseline) and then weekly using the European Organization Research Treatment Cancer Core Quality Life Questionnaire Core-30 questionnaire. Patients...
Controversy exists whether the prostate-specific antigen (PSA) bounce phenomenon following definitive radiation for prostate cancer has prognostic significance. Here, we perform a meta-analysis to determine association between PSA and biochemical control after brachytherapy alone.We reviewed Medline, EMBASE, CENTRAL citations through February 2012. Studies that recorded failure rates in bouncers non-bouncers were included. Hazard ratios describing impact of on extracted directly from studies...
8510 Background: Standard therapy for unresectable locally advanced non-small cell lung cancer (LA-NSCLC) is concurrent chemoradiotherapy followed by adjuvant durvalumab. We performed a prospective trial testing sequential pembrolizumab and risk-adapted radiotherapy without chemotherapy biomarker-selected LA-NSCLC patients. Methods: Patients with stage III NSCLC or II NSCLC, ECOG performance status 0-1, no contraindications to protocol-specified were eligible this trial. Subjects PD-L1 tumor...
ENWEndNote BIBJabRef, Mendeley RISPapers, Reference Manager, RefWorks, Zotero AMA Kuo H, Mehta K, Hong L, et al. Original paperDay to day treatment variations of accelerated partial breast brachytherapy using a multi-lumen balloon. Journal Contemporary Brachytherapy. 2014;6(1):68-75. doi:10.5114/jcb.2014.42025. APA Kuo, H., Mehta, K., Hong, L., Yaparpalvi, R., Montgomery, & Bodner, W. (2014). Brachytherapy, 6(1), 68-75. https://doi.org/10.5114/jcb.2014.42025 Chicago Hsiang-Chi, Keyur J....
9618 Background: In a murine non-small cell lung cancer (NSCLC) model, we demonstrated synergy between localized radiotherapy and the dendritic growth factor fms-like tyrosine kinase 3 (FLT3) ligand. We now present results from phase II study testing this combination in patients with advanced treatment-refractory NSCLC. Methods: Advanced NSCLC multifocal active disease after at least one line of systemic therapy ECOG performance status 0-2 received 5 daily subcutaneous injections CDX-301 (75...
For most locally advanced non-small cell lung cancer (LA-NSCLC) patients who complete definitive chemoradiotherapy (CRT) and do not experience disease progression, one year of adjuvant durvalumab is recommended. Here, we explore causes consequences early discontinuation.
The Photon Radiosurgery System (PRS), developed by the Photoelectron Corporation in Lexington, Massachusetts, produces low-energy x-rays from tip of a needle-like probe at high dose-rate. This portable device can be located directly over target volume, delivering uniform dose while sparing surrounding normal structures. To evaluate its radiotherapeutic profile, prospective phase I Food and Drug Administration trial was performed utilizing this management nonmelanomatous skin cancers. Target...
Abstract Background We previously demonstrated, in a murine model, that localized radiotherapy and fms-like tyrosine kinase 3 (FLT3) ligand can act synergistically to control non-small cell lung cancer (NSCLC). Here we present preliminary results from an ongoing prospective clinical trial testing this combination patients with advanced NSCLC. Methods Patients NSCLC has been treated at least one line of systemic therapy, two sites active disease based on pre-treatment FDG-PET, ECOG...